B-cell chronic lymphocytic leukemia (B-CLL) is a heterogenous disease with a highly variable clinical course. Recent studies have shown that expression of the protein tyrosine kinase ZAP-70 may serve as a prognostic marker in B-CLL. Employing a semiquantitative RT-PCR assay, we examined purified leukemia B cells of 39 CLL patients for the expression of ZAP-70 mRNA transcripts. Significant ZAP-70 mRNA levels exceeding those found in control samples with 5% T cells were detected in 36% of the CLL cases. Patients in the ZAP-70 positive cohort were characterized by an unfavorable clinical course with a significantly shorter progression-free survival as compared to the ZAP-70-negative patients (64%). These results were confirmed by flow-cytometric analysis of the ZAP-70 protein, and expanded to a larger patient cohort (n ¼ 67). A combined statistical analysis of 79 patients showed that the two patient subgroups also differed with regard to overall survival and a panel of known clinical prognostic factors including LDH, thymidine kinase serum levels and expression of the CD38 surface antigen by the leukemic cell clone. The level of ZAP-70 expression did not change over time in the majority of patients where sequential samples were available for analysis.
Introduction
B-cell chronic lymphocytic leukemia (B-CLL) is a heterogenous disease with a highly variable clinical course. Staging systems devised by Rai et al 1 and Binet et al 2, 3 are useful methods for predicting survival and treatment requirements in patients with CLL. However, these staging systems are of limited prognostic value in the early stages of the disease (Binet A or Rai stage 0-II), which include most of the patients at diagnosis. Therefore, a number of studies have focused on identifying novel prognostic markers, which may help define patient subgroups with favorable vs poor clinical outcome in early CLL. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] In the context of these studies, the presence or absence of somatic mutations in the immunoglobulin heavy-chain variable region (IgV H ) of B-CLL cells has been described as one of the most powerful prognostic factors, where B-CLL cases with mutated IgV H genes exhibit a favorable clinical course while B-CLL patients with unmutated Ig V H genes are characterized by a poor outcome in terms of reduced survival and responsiveness to chemotherapy. However, IgV H sequencing is difficult to perform in a routine diagnostic laboratory, and thus this assay is currently unavailable to most of the CLL patients.
In a pioneering gene expression profiling study, Rosenwald et al 15 identified a panel of genes that could predict the IgV H mutational status of the CLL cells with high accuracy. Recently, these authors expanded their study to a larger cohort of 107 patients, demonstrating that expression analysis of a single gene, that is, the protein tyrosine kinase ZAP-70, could correctly predict the IgV H mutation status in 93% of patients. 14 Thus, ZAP-70 gene expression may be used as a convenient surrogate marker of IgV H mutation in a routine laboratory setup. However, until now, there is a lack of information regarding the clinical value of this novel prognostic marker.
Here, we report a single center retrospective study of 79 CLL patients evaluating the potential of ZAP-70 expression as a prognostic factor. To this end, we measured the level of ZAP-70 expression in peripheral blood (PB) samples from 79 patients with B-CLL, using a simple semiquantitative RT-PCR assay and flow cytometry, and correlated our results with known risk factors such as thymidine kinase and b2-microglobulin serum levels, expression of the CD38 surface antigen by the leukemic cell clone and clinical outcome.
Materials and methods

Patients and isolation of CLL cells
Between July 2002 and June 2003, 79 patients with CLL were enrolled in this retrospective study and analyzed for several biological and clinical characteristics: Binet stage, lactate dehydrogenase, thymidine kinase, treatment history and time from diagnosis to first treatment. In each patient, the morphologic diagnosis of B-CLL was confirmed by flow cytometry revealing a typical CD19 þ , 20 þ , 5 þ , 23 þ , Ig light chain (k or l light chain) restricted immunophenotype. Heparinized whole PB samples were usually obtained during routine followup visits to our institution, with informed consent according to institutional guidelines. Patients were selected based on the availability of fresh samples and the absence of treatment at the time of inclusion into the study. Mononuclear cells (PBMNC) were isolated by Ficoll-Paque (Pharmacia, Erlangen, Germany) density centrifugation and washed in Iscove's Modified Dulbecco's Medium (Gibco BRL, Karlsruhe, Germany). Thereafter, B cells were purified using the CD19 magnetic bead system (Miltenyi Biotec, Bergisch-Gladbach, Germany). CD19 selection resulted in 498% purity and contamination with CD3-positive T cells in all samples was o2%, as analyzed by flow cytometry.
In a second series of experiments, the ZAP-70 RT-PCR data were validated using flow-cytometric analysis of the ZAP-70 protein (see below) in 67 CLL patients. In 28 of these individuals, both flow cytometry and RT-PCR were employed independently to determine the ZAP-70 expression status of the leukemic cell clone ( Figure 5 ). Patient selection in this second set of experiments was based on the availability of viably frozen PBMNC stored in our CLL cell bank.
Indications for previous treatment of the patients were based on standard criteria. 16 Of a total of 79 patients, 36 (46%) had previously received chemotherapy, and first-line therapy consisted of chlorambucil in 31 of these patients. Initial treatment in the remaining five patients consisted of fludarabine-based regimens.
Cell surface staining and flow cytometry
For the determination of CD38 expression, fresh heparinized PB samples were prepared for flow cytometry by ammonium chloride erythrocyte lysis (Ortho-muneTM Lysing Reagent, Ortho Diagnostic Systems Inc., Raritan, NJ, USA). The immunophenotype was characterized using a standard three-color flow-cytometry approach, as previously described. 6 Antibodies were purchased from DAKO (Glostrup, Denmark; CD19, CD10, IgM, k and l light chains), Immunotech (Marseille, France; CD5) and Becton Dickinson (Heidelberg, Germany; CD38, CD4, CD8, CD3). Negative isotype-matched controls (Becton Dickinson) were used to define the threshold line separating surface marker positive and negative cells, such that less than 1% of isotype-positive cells were present to the right of the line. A CLL population was considered CD38 positive when more than 20% of the gated population (CD19 þ /5 þ ) expressed it. The same method of sample preparation and three-color staining was used throughout the entire study period. Samples were analyzed on a FACScan flow cytometer (Becton Dickinson) using CellQuest software (Becton Dickinson).
Semiquantitative RT-PCR
Total RNA from 1-2 to 10 8 CD19-purified CLL cells was extracted, purified using the RNeasy midi kit (Qiagen, Hilden, Germany), and quantified spectrophotometrically. First-strand cDNA was synthesized from 1 mg of RNA using oligo(dT) primers employing a commercially available kit (RT-PCR Amplimers, Becton Dickinson, Heidelberg, Germany) according to the manufacturer's instructions. A volume of 5 ml of cDNA was added to a final PCR reaction mixture of 50 ml, containing 1 ml of Taq polymerase (50 Â titanium DNA polymerase, Becton Dickinson), the recommended buffer (10 Â titanium Taq PCR buffer), 1 ml dNTP Mix (10 mM), 2 ml of 20 mM GPDH control primers (forward primer: 5 0 -3 0 : TGAAGGTCGGAGTCAACGGA-TTTGGT, reverse primer 5 0 -3 0 : CATGTGGGCCATGAGGTC-CACCAC; Becton Dickinson) and 2 ml of 20 mM ZAP-70-specific primers (forward primer 5 0 -3 0 : TCTCCAAAGCACTGGGTG, reverse primer 5 0 -3 0 : AGCTGTGTGTGGAGACAACCAAG) 15 and 34 ml of H 2 O. Each of 30 PCR amplification cycles consisted of a heat denaturation (951C for 60 s), annealing (691C for 90 s) and extension step (681C for 180 s). Control reactions were performed using the same conditions omitting the RT reaction. The PCR products were resolved on ethidium bromide-stained 2.0% agarose gel and UV photographed. Then, the amounts of PCR products were evaluated according to the relative intensity of ZAP-70 and GPDH bands by using the computed densitometry assay of the Biometra BioDoc Analyze System (Biometra, Gö ttingen, Germany).
Determination of ZAP-70 protein using flow cytometry
Flow-cytometric analysis of ZAP-70 was performed using the method recently described by Crespo et al, 17 with minor modifications. Briefly, thawed PBMNC from 67 patients with B-CLL were fixed and permeabilized using the Fix & Perm kit (Caltag Laboratories, Hamburg, Germany), according to the manufacturer's instructions. Then, 1. 
Statistical analysis
Progression-free survival times were measured from the time of diagnosis, plotted by the Kaplan-Meier method and compared using the log-rank test. Comparison of clinical and laboratory parameters between patient subgroups was performed using the Mann-Whitney U-test for metric data, Fisher's exact test and the w 2 test for categorial data.
Results
ZAP-70 expression in the B-CLL study group
Based on recent studies showing that ZAP-70 is a surrogate marker of IgV H mutation status in B-CLL, 14, 15, 17, 18 we investigated whether expression of ZAP-70 mRNA may serve as a prognostic factor in our CLL patient cohort. To this end, we developed a simple semiquantitative RT-PCR assay using total RNA from immunomagnetically purified CLL cells (purity 498%). ZAP-70 was found to be abundantly expressed in circulating T cells, but not in B cells and monocytes isolated from normal donors ( Figure 1a ). ZAP-70 transcripts were also detected in immunomagnetically purified T cells from CLL patients ( Figure 1a ) and, thus, contaminating T cells may yield false-positive results under these experimental conditions. For this reason, we isolated RNA from mixtures of highly purified ZAP-70-negative CLL cells (purity 99%) and immunomagnetically enriched normal T cells (purity 495%) to determine a possible cutoff value for ZAP-70 expression (Figure 1b ). Based on these experiments, samples exhibiting a ZAP-70/GPDH ratio X0.13 were defined as ZAP-70 positive (14/39; 36%) and those with a ZAP-70/GPDH ratio o0.13 as ZAP-70 negative (25/39; 64%; Figure 1c ). Figure 1d shows the distribution of ZAP-70/ GPDH ratios in the whole patient cohort.
Importantly, comparing these two subgroups with regard to their clinical characteristics, we found highly significant differences in disease progression, as indicated by the treatment-free interval ( Figure 2 ). The mean treatment-free interval was longer in the ZAP-70À (146 months) than in the ZAP-70 þ patient cohort (100 months, P ¼ 0.0019; Figure 2 ).
In a second set of experiments, we tried to validate our observation that ZAP-70 may serve as an adverse prognostic factor in B-CLL. To this end, we employed a flow-cytometry assay, recently described by Crespo et al, 17 to measure the level of ZAP-70 protein in B-CLL cells from 67 patients. The method used to quantify the percentage of B-CLL cells expressing as much ZAP-70 protein as accessory T cells contained in the same PBMNC sample is shown in Figure 3a . As per current convention, a CLL population was considered ZAP-70 positive when more than 20% of the gated population (CD19 þ B cells) expressed it. 17 Based on this 20% cutoff value, 34/67 patients (51%) were defined as ZAP-70 positive and 33/67 patients (49%) as ZAP-70 negative, respectively. Again, when the treatment-free interval was calculated from the time of diagnosis, the patients with at least 20% ZAP-70 þ CLL cells had a mean progression-free survival of 38 months as compared to 120 months in their ZAP-70À counterparts ( Figure 4 , P ¼ 0.008), confirming our data obtained with the semiquantitative PCR assay (Figure 2 ). In 28 patients both, RT-PCR and flow cytometry, were employed independently to determine the ZAP-70 expression status of the leukemic cell clone ( Figure 5 ). In all but two patients, there was complete concordance of ZAP-70 expression, as assessed by RT-PCR and flow cytometry.
Correlation of ZAP-70 expression with clinical and laboratory data
For further statistical analysis, the clinical and laboratory data of the two assays used to discriminate ZAP-70 þ and ZAP-70À patients were pooled -that is, 35 ZAP-70 þ patients were compared with 42 ZAP-70À patients. The two patients (patients #2 and #22, Figure 5 ) with inconsistent results for ZAP-70 expression in the RT-PCR and the flow-cytometry assay were excluded from this analysis.
The treatment histories of ZAP-70-positive and ZAP-70-negative patients differed significantly (Table 1) in that the former group required more intensive chemotherapy over longer time periods than ZAP-70 negative patients (P ¼ 0.0001).
The higher treatment intensities in ZAP-70-positive patients correlated with a more advanced disease stage at study enrollment but not at diagnosis (Table 2) . Finally, we compared the overall survival among the two groups, and again observed statistically significant differences ( Figure 6 ). The mean survival of patients in the ZAP-70 positive cohort was 139 months, whereas the mean survival for the ZAP-70 negative group was not reached during the duration of follow-up (P ¼ 0.013).
A comparison of further clinical and laboratory parameters among the two groups is shown in Table 2 . Notably, significant differences were found for Binet stage at study enrollment, ZAP-70 expression is a prognostic factor J Dürig et al lactate dehydrogenase, b2-microglobulin, thymidine kinase, bone marrow histology and CD38 expression (Po0.05).
Correlation between ZAP-70 and CD38 expression
Data for the expression of CD38 were available for 76/77 (99%) patients with known ZAP-70 expression. Figure 7 shows the correlation of the level of CD38 expression and ZAP-70 expression status. As can be seen, in 63/76 patients (83%), there was a complete concordance of ZAP-70 and CD38 expression (Figure 7a) . However, the remaining 13 patients (17%) revealed discordant results, with a majority (9/76; 12%) showing a ZAP-70 þ /CD38À phenotype.
Next, we investigated whether the expression of CD38 could further refine the clinical relevance of ZAP-70 as an adverse prognostic factor. In accordance with our own previous work 6 and that of others, 10, 19 CD38 expression (using a 20% cutoff) on its own was associated with a significantly shorter progressionfree survival as compared to the CD38À patient cohort (Figure 8a) . Interestingly, we found that the ZAP-70 þ /CD38À subgroup is characterized by a longer progression-free survival than the ZAP-70 þ /CD38 þ cohort (Figure 8c) , suggesting that the combination of these two parameters may increase the prognostic power of either of the two factors. However, the subgroup analysis shown in Figure 8c is based on nine patients and needs to be confirmed in a larger patient cohort. 
ZAP-70 expression is a prognostic factor J Dürig et al
Analysis of ZAP-70 expression over time
Seven patients (five ZAP-70-negative and two ZAP-70-positive patients) were studied at two or more time points using the RT-PCR assay. As illustrated in Figure 9a , ZAP-70 mRNA expression in these individual patients was relatively stable over time in all of the patients analyzed. This was also true for the majority of patients, in whom sequential samples were analyzed by flow cytometry (Figure 9b) . However, in a minority of these patients (#15, 33, 38 and 69), we observed substantial variations in ZAP-70 expression over time (Figure 9b ). Further analysis of the clinical characteristics of these four patients (data not shown) did not reveal a consistent pattern linking changes in ZAP-70 expression with disease progression, and none of these patients received cytotoxic treatment between the two measurements.
Correlation of the level of expression of ZAP-70 and CD38 in individual B-CLL patients
A three-color flow-cytometry approach using a ZAP-70/CD38/ CD19 antibody combination allowed us to determine whether ZAP-70 may be coregulated with the CD38 antigen in B-CLL cell clones from individual patients. To this end, we selected PBMNC samples that had previously been shown to contain B50% CD38 þ B-CLL cells. Figure 10a shows the gating strategy used to compare CD38 þ with CD38À B-CLL cells within individual patients (N ¼ 5). Interestingly, CD38 þ cells exhibited a significantly higher ZAP-70 expression than their CD38À counterparts (Figure 10b ).
Discussion
We performed a retrospective study to evaluate the potential of ZAP-70 expression as a prognostic indicator in B-CLL. Immunomagnetically purified leukemic cells from 39 CLL patients were analyzed for ZAP-70 gene expression, employing a simple semiquantitative RT-PCR assay. Significant ZAP-70 mRNA levels exceeding those found in control samples with 5% T cells were detected in 36% of the CLL cases. Importantly, we found that patients with ZAP-70-positive CLL were characterized by a more aggressive clinical course as compared to the ZAP-70-negative patients. In particular, our data show significant differences in terms of progression-free survival between the two groups, confirming two recently published studies by Wiestner et al 14 and Crespo et al.
17
However, the semiquantitative RT-PCR assay used for our initial experiments required the time-consuming isolation of the leukemic cell population prior to analysis, limiting its applicability in a routine laboratory setting. Thus, in a second set of experiments, we tried to validate our data by employing a flowcytometry assay, recently described by Crespo et al 17 to measure the level of ZAP-70 protein in B-CLL cells from 67 patients. Reassuringly, using the previously described cutoff value of 20% for ZAP-70 positivity, 17 the flow-cytometry assay yielded The P-value was calculated using the w 2 test.
ZAP-70 expression is a prognostic factor J Dürig et al comparable results in the Kaplan-Meier analysis of progressionfree survival (see Figures 2 and 4) . Also, largely concordant results were observed, when both, RT-PCR and flow cytometry, were employed independently to determine the ZAP-70 expression status in 28 patients. The more aggressive clinical course of ZAP-70-positive patients as indicated by the shorter mean progression-free and overall survival as compared to the ZAP-70-negative patient cohort also correlated with other known clinical risk factors such as Binet disease stage, lactate dehydrogenase, b2-microglobulin, thymidine kinase, bone marrow histology and CD38 expression. Furthermore, treatment histories between the two groups differed significantly in that the patients with a high expression of ZAP-70 required more chemotherapy than the remaining patients.
Serial analyses in seven of the patients followed by RT-PCR revealed relatively stable ZAP-70 mRNA levels over an observation period of up to 8 months in all cases tested. However, in a minority of the patients analyzed by flow cytometry, substantial variations in the level of ZAP-70 protein were observed (Figure 9 ), contrasting in part the results reported by Crespo et al, 17 who found stable ZAP-70 protein levels in sequential samples from 30 patients. These discrepancies are reminiscent of the controversial results regarding the stability of CD38 expression over time 6, 20 and thus, this issue needs to be addressed in a larger patient cohort.
Recently, Lin et al 19 showed that the poor outcome of patients without somatic mutations in the immunoglobulin heavy-chain variable region (IgV H ) may be due to the over-representation of high-risk patients with p53 dysfunction and/or CD38 positivity within this group, and that CD38-negative patients with functionally intact p53 may have a prolonged survival regardless of the IgV H mutation status. Thus, we next investigated whether the expression of CD38 could further refine the clinical relevance of ZAP-70 as an adverse prognostic factor. To this end, after having confirmed the prognostic value of CD38 in our patient cohort (Figure 8a) we then determined the relation of CD38 and ZAP-70 expression in individual patients (Figure 7 ). Similar to other recent studies 14, 17, 21 we found that CD38 and ZAP-70-positive CLL cases represent overlapping but not identical patient populations (Figure 7) . Interestingly, in accordance with the results reported by Lin et al, we observed that CD38À/ZAP-70 þ and CD38À/ZAP-70À patients exhibited comparable treatment-free survival curves (Figure 8c ), suggesting that the combination of these two parameters may increase the prognostic power of either of the two factors. However, this subgroup analysis is based on nine patients and needs to be confirmed in a larger patient cohort.
The molecular mechanisms underlying 'aberrant' ZAP-70 expression in B-CLL cells and its functional implications for the biological behavior of the malignant cell clone are currently unknown. Intriguingly, Chen et al 21 have demonstrated that BCR stimulation in CLL cells results in tyrosine phosphorylation and Table 2 Comparison of clinical and laboratory data between ZAP-70-positive and ZAP-70-negative patients The P-value is for the comparison among the ZAP-70-positive and ZAP-70-negative subgroups, and was calculated using the w 2 test.
c
The P-value is for the comparison among the ZAP-70-positive and ZAP-70-negative subgroups, and was calculated using the Mann-Whitney U-test. 
Figure 6
Overall survival of ZAP-70-negative (n ¼ 42) and ZAP-70-positive (n ¼ 35) CLL patients (as assessed by RT-PCR and/or flow cytometry). Kaplan-Meier plots comparing survival based on the expression of ZAP-70. Statistical analysis was performed using the logrank test.
ZAP-70 expression is a prognostic factor J Dürig et al translocation of ZAP-70 to the plasma membrane, where it becomes associated with surface immunoglobulin and CD79b, arguing for the involvement of ZAP-70 in BCR signaling. Furthermore, recent studies have shown that ZAP-70 is tyrosine phosphorylated in response to antibody-mediated CD38 stimulation in NK 22 and T cells, 23 raising the possibility that it may also play a role in CD38 signaling in B-CLL. This notion is also supported by our finding that the levels of the ZAP-70 and CD38 proteins may be coregulated in indvidual cells of a given CLL ZAP-70 expression is a prognostic factor J Dürig et al clone ( Figure 10 ). However, further work is needed to better understand the potential role of ZAP-70 in the pathogenesis of CLL.
In conclusion, our data confirm previous studies showing that ZAP-70 expression is a novel prognostic marker in B-CLL. Furthermore, our results and those of others 19 suggest that a combination of prognostic factors such as ZAP-70 and CD38 may help optimize currently available prognostic instruments for the risk stratification of CLL patients in clinical trials. ZAP-70 expression is a prognostic factor J Dürig et al
